Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Adverum Biotechnologies Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ADVM
Nasdaq
8731
https://adverum.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Adverum Biotechnologies Inc
Adverum Biotechnologies Granted Priority Medicines (PRIME) Designation by European Medicines Agency for ADVM-022 in Wet AMD
- Jun 24th, 2022 12:00 pm
Adverum Biotechnologies Presents Three-Year Aflibercept Protein Expression and Improvement in Anatomic Outcomes After a Single IVT Injection of ADVM-022 in the OPTIC Study in Wet AMD
- Jun 9th, 2022 12:00 pm
Adverum Biotechnologies Announces New Data at the Macula Society’s 2022 Annual Meeting
- Jun 2nd, 2022 8:05 pm
Adverum Biotechnologies Presents Research Pipeline Data Supporting Utility of its Proprietary Platform and AAV.7m8 Capsid in Ocular Gene Therapy
- May 19th, 2022 12:00 pm
Adverum's Data at ASGCT Further Supports Phase 2 Development Plans For Wet-AMD Gene Therapy
- May 18th, 2022 12:11 pm
Adverum Presents Data at ASGCT Further Supporting Phase 2 Development Plans for ADVM-022
- May 17th, 2022 8:05 pm
Adverum Biotechnologies Reports First Quarter 2022 Financial Results
- May 12th, 2022 8:05 pm
How Much Of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Do Institutions Own?
- May 11th, 2022 6:51 pm
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- May 9th, 2022 8:05 pm
Adverum Biotechnologies Announces Upcoming Data Presentations at ASGCT 2022
- May 2nd, 2022 8:30 pm
Adverum Bio Posts Additional Efficacy, Safety Data From ADVM-022 Gene Therapy In Wet AMD
- May 2nd, 2022 10:59 am
Adverum Biotechnologies Presents Additional Efficacy and Safety Data from the OPTIC Trial of ADVM-022 in Wet AMD at the ARVO 2022 Annual Meeting
- May 1st, 2022 6:15 pm
Adverum Biotechnologies Announces Upcoming Data Presentations at ARVO 2022
- Apr 19th, 2022 10:00 pm
Adverum (ADVM) Up on FDA Feedback for Gene Therapy Study
- Apr 7th, 2022 6:50 pm
Adverum Moves Forward With IND Amendment For ADVM-022 Phase 2 Trial In Wet AMD
- Apr 7th, 2022 11:30 am
Adverum Biotechnologies Proceeds with IND Amendment for ADVM-022 Phase 2 Trial in Wet AMD After Receiving Requested Type C Meeting Feedback from the FDA
- Apr 6th, 2022 8:05 pm
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2021 Financial Results
- Mar 29th, 2022 8:05 pm
Adverum Appoints Rabia Gurses Ozden, M.D. and Soo J. Hong, M.B.A., to Board of Directors
- Mar 17th, 2022 8:05 pm
Should You Buy Adverum Biotechnologies (ADVM) Ahead of Earnings?
- Mar 2nd, 2022 5:11 pm
Adverum Biotechnologies to Participate in the 42nd Annual Cowen Healthcare Conference
- Feb 28th, 2022 1:00 pm
Scroll